Amp Volatility Score
Catalyst Info & Data Links
TITLE: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) - Phase 1/2 Data
ClinicalTrial.gov (NCT04398433): INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
WHAT IS THE CATALYST EVENT?
Phase 1/2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Recurrent respiratory papillomatosis (RRP) is a rare disease (estimated at 15,000 active cases in the U.S.) that is characterized by the growth of tumors in the respiratory tract caused by the human papillomavirus. Although benign, papillomas can cause severe, even life-threatening airway obstruction and respiratory complications. A distinguishing aspect of this disease is the tendency for the papilloma to recur after surgical procedures to remove them. Left untreated, if RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In rare cases papillomas can become cancerous (malignant transformation) developing into squamous cell carcinoma. Additional symptoms of RRP can include hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. In children, the disorder is most often diagnosed at or around the age of four years. In adults, the disorder occurs most often in the third or fourth decade.
Updated by HC
INO, Recurrent Respiratory Papillomatosis (RRP), INO-3107, benign (noncancerous) tumors, lungs (respiratory tract), rare diseases
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post